Nuvation Bio

Update in progress

NUVB (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nuvation Bio is a clinical-stage biopharmaceutical company focused on cancer therapies. Its lead candidate, IBTROZI (taletrectinib), is a ROS1 inhibitor for ROS1-positive non-small cell lung cancer. The company is also advancing Safusidenib, an IDH1-mutant inhibitor in phase 3 trials for maintenance therapy in high-risk IDH1-mutant astrocytoma versus placebo. Founded in 2018 and based in New York City.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive